Service de chirurgie hépatobiliaire et digestive, CHU Pontchaillou, Université Rennes I, Rennes, France.
Ann Surg Oncol. 2010 Dec;17(12):3155-61. doi: 10.1245/s10434-010-1168-z. Epub 2010 Jul 1.
Long-term survival after complete resection of hilar cholangiocarcinoma remains disappointing. The aim of this retrospective study was to assess the impact of liver optimization on postoperative outcome of hilar cholangiocarcinoma type III.
In a retrospective, single-center analysis, outcomes in patients with hilar cholangiocarcinoma type III who underwent resection after preoperative liver optimization (preoperative transhepatic biliary drainage [PTBD], bile replacement, and/or portal vein embolization [PVE]) were compared with nonoptimized controls.
Of 41 patients undergoing surgery, 38 patients undergoing curative intent procedures were identified, of whom 15 underwent preoperative optimization. After PTBD, direct bilirubin decreased from 218.0 ± 184.2 to 75.9 ± 42.7 μmol/L (P = 0.03), and there was a trend toward decreased AST and ALT levels. Overall, 3- and 5-year survival rates were 47.9 ± 9.1 and 41.9 ± 9.8%. The primary endpoint, 5-year survival after surgery, was not significantly different between groups. Preoperative jaundice was identified as an independent prognostic factor for poor outcome (hazard ratio [HR] 2.12, P = 0.02). Four patients (10.5%) without preoperative optimization died of liver failure within the first 30 days postsurgery, preceded in three cases by intra-abdominal abscesses. PTBD was associated with a lower rate of postoperative intra-abdominal abscesses; however this factor was not independently predictive of higher survival.
Preoperative optimization of the liver in hilar cholangiocarcinoma Type III reduced the incidence of intra-abdominal abscesses, but its impact on postoperative survival remains unclear.
肝门部胆管癌完全切除后的长期生存仍然令人失望。本回顾性研究旨在评估术前肝脏优化对肝门部胆管癌 III 型术后结局的影响。
在一项回顾性、单中心分析中,比较了接受术前肝脏优化(术前经肝内胆管引流[PTBD]、胆汁替代和/或门静脉栓塞[PVE])后行切除术的肝门部胆管癌 III 型患者与未优化对照组的结局。
在 41 例接受手术的患者中,确定了 38 例接受根治性手术的患者,其中 15 例接受了术前优化。PTBD 后,直接胆红素从 218.0±184.2μmol/L 降至 75.9±42.7μmol/L(P=0.03),AST 和 ALT 水平呈下降趋势。总体而言,3 年和 5 年生存率分别为 47.9±9.1%和 41.9±9.8%。手术 5 年后的主要终点生存率在两组之间无显著差异。术前黄疸被确定为不良预后的独立预测因素(风险比[HR]2.12,P=0.02)。4 例(10.5%)未行术前优化的患者术后 30 天内死于肝功能衰竭,其中 3 例患者术前合并腹腔脓肿。PTBD 与术后腹腔脓肿发生率降低相关;然而,这一因素并不能独立预测更高的生存率。
肝门部胆管癌 III 型的术前肝脏优化降低了腹腔脓肿的发生率,但对术后生存的影响尚不清楚。